Showing results (221-230 of 261) with videos related to
Sort By:
Pageof 27
Journal of the American Academy of Dermatology|January 16, 2018
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis FoundationScott M Whitlock, Clinton W Enos, April W Armstrong, et al.Journal of the American Academy of Dermatology|February 23, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension studyKim A Papp, James G Krueger, Steven R Feldman, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 11, 2025
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, Mahreen Ameen, H Chih-Ho Hong, et al.Journal of the American Academy of Dermatology|February 15, 2001
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility studyM Elbaum, A W Kopf, H S Rabinovitz, et al.Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.Journal of the American Academy of Dermatology|April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trialAndrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.The British Journal of Dermatology|February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)D Thaci, S Piaserico, R B Warren, et al.JAAD International|February 3, 2025
Optimizing the management of psoriasis in patients with skin of color: A Canadian Delphi consensusGeeta Yadav, Yvette Miller-Monthrope, Jaggi Rao, et al.Pageof 27